Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ichthammol→

Ichthammol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8029-68-3
Molecular formula
Not available
Molecular weight
76.055 g/mol
Drug class
Sulfonated shale-oil derivativetopical anti-inflammatory and antiseptic ingredient
Mechanism of action
A complex sulfonated shale-oil preparation with reported local anti-inflammatory, antimicrobial and antipruritic effects. Proposed anti-inflammatory actions include inhibition of lipoxygenase and cyclooxygenase pathways; the composition is a mixture rather than a single molecular drug.
Indications / reported uses
  • Topical use in selected inflammatory skin preparations and drawing-salve products; specific indications depend on the registered formulation. Some US OTC ichthammol labels are marketed as unapproved homeopathic products and should not be treated as evidence of established efficacy.

Sources: https://www.ichthyol.de/en/raw-materials-for-corporate-customers/ichthammol/ · https://www.ndf.gov.sg/about-drugs/active-ingredient/m00462/ · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdbeeb95-5c46-9a24-e053-2a95a90aa397

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ichthammol Environmental Risk Assessment (ERA) (the Ichthammol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.